SAB Biotherapeutics has presented positive safety and pharmacologic data from a GLP toxicology study for its first-in-class fully human immunotherapeutic, SAB-142, at FOCIS 2023. The treatment is being developed to delay onset and progression of Type 1 Diabetes (T1D) by targeting multiple immunological cell subsets associated with T1D and other autoimmune diseases. Results from the study showed that SAB-142 affects the same subsets of immune cells associated with T1D as commercially available rabbit-derived anti-thymocyte globulin in vivo.
The study confirms that the fully-human multi-target immune modulating therapeutic is well tolerated and affects the same subsets of immune cells associated with T1D as commercially available rabbit-derived anti-thymocyte globulin in vivo.
SAB plans to submit an IND application to the FDA and initiate a Phase 1 trial in the next few months.
Keywords: SAB Biotherapeutics, GLP toxicology study, SAB-142, immunotherapeutic, Type 1 Diabetes. SAB Biotherapeutics has announced positive results